These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18676347)

  • 41. Sudden cardiac death and mineral metabolism in chronic kidney disease.
    Afsar B; Elsurer R
    Kidney Int; 2010 Apr; 77(7):648; author reply 648-9. PubMed ID: 20224591
    [No Abstract]   [Full Text] [Related]  

  • 42. [Parathormone and chronic kidney disease].
    Bacchetta J; Jolivot A; Souberbielle JC; Charrié A; Guebre F; Chauvet C; Fouque D
    Nephrol Ther; 2007 Jul; 3(4):133-8. PubMed ID: 17658439
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Uremia: formulations and expectations. The trade-off hypothesis: current status.
    Bricker NS; Fine LG
    Kidney Int Suppl; 1978 Jun; (8):S5-8. PubMed ID: 278898
    [No Abstract]   [Full Text] [Related]  

  • 44. [The challenge of hyperphosphatemia control in chronic kidney disease].
    Lorenzo Sellares V
    Nefrologia; 2008; 28 Suppl 5():3-6. PubMed ID: 18847412
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The bone-renal axis in early chronic kidney disease: an emerging paradigm.
    Danziger J
    Nephrol Dial Transplant; 2008 Sep; 23(9):2733-7. PubMed ID: 18469306
    [No Abstract]   [Full Text] [Related]  

  • 46. Early detection of CKD will reduce heart disease risk.
    Sangala N; Goldsmith D
    Practitioner; 2009 Apr; 253(1717):24-7. PubMed ID: 19462743
    [No Abstract]   [Full Text] [Related]  

  • 47. The Effects of Intensive Blood Pressure Lowering on Markers of Mineral Metabolism in Persons with CKD in SPRINT.
    Ginsberg C; Katz R; Chonchol MB; Bullen AL; Raphael KL; Zhang WR; Ambrosius WT; Bates JT; Neyra JA; Killeen AA; Punzi H; Shlipak MG; Ix JH
    Clin J Am Soc Nephrol; 2020 Jun; 15(6):852-854. PubMed ID: 32376678
    [No Abstract]   [Full Text] [Related]  

  • 48. Impaired GFR is the most important determinant for FGF-23 increase in chronic kidney disease.
    Filler G; Liu D; Huang SH; Casier S; Chau LA; Madrenas J
    Clin Biochem; 2011 Apr; 44(5-6):435-7. PubMed ID: 21291879
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Normocalcemic hyperparathyroidism.
    Zechner O; Kovarik J; Willvonseder R
    Eur Urol; 1981; 7(6):327-30. PubMed ID: 7286000
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [FGF-23 in primary and secondary hyperparathyroidisms].
    Imanishi Y; Kobayashi K
    Nihon Rinsho; 2005 Oct; 63 Suppl 10():539-44. PubMed ID: 16279697
    [No Abstract]   [Full Text] [Related]  

  • 51. [Chronic kidney disease (CKD) and bone. Chronic kidney disease--mineral and bone disorder in predialysis patients].
    Inaguma D; Tatematsu M
    Clin Calcium; 2009 Apr; 19(4):493-9. PubMed ID: 19329827
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The fibroblast growth factor 23: a new player in the field of cardiovascular, bone and renal disease.
    Cozzolino M; Mazzaferro S
    Curr Vasc Pharmacol; 2010 May; 8(3):404-11. PubMed ID: 20180772
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CKD prognosis: beyond the traditional outcomes.
    Coresh J
    Am J Kidney Dis; 2009 Jul; 54(1):1-3. PubMed ID: 19559334
    [No Abstract]   [Full Text] [Related]  

  • 54. Critical issues of PTH assays in CKD.
    Komaba H; Goto S; Fukagawa M
    Bone; 2009 Apr; 44(4):666-70. PubMed ID: 19159701
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FGF23: fashion or physiology?
    Wolf M
    Clin J Am Soc Nephrol; 2010 Oct; 5(10):1727-9. PubMed ID: 20847097
    [No Abstract]   [Full Text] [Related]  

  • 56. Pathogenic approach to the hypophosphataemia of renal transplantation.
    Plaza JJ; Castrillo JM; Alvarez V; Rapado A; Hernando L
    Proc Eur Dial Transplant Assoc; 1981; 18():380-6. PubMed ID: 7036156
    [No Abstract]   [Full Text] [Related]  

  • 57. Emerging topics in pediatric bone and mineral disorders 2008.
    McKay CP; Portale A
    Semin Nephrol; 2009 Jul; 29(4):370-8. PubMed ID: 19615558
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients.
    Guideline Working Group, Japanese Society for Dialysis Therapy
    Ther Apher Dial; 2008 Dec; 12(6):514-25. PubMed ID: 19140852
    [No Abstract]   [Full Text] [Related]  

  • 59. Calcium malabsorption does not cause secondary hyperparathyroidism.
    Nordin BE; Morris HA; Horowitz M; Coates PS; O'Loughlin PD; Need AG
    Calcif Tissue Int; 2009 Jul; 85(1):31-6. PubMed ID: 19488668
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Elevated fibroblast growth factor 23 levels in a newborn with secondary hypoparathyroidism.
    Bech A; Nabbe K; Brussel W; Telting D; de Boer H
    Pediatrics; 2010 Dec; 126(6):e1613-6. PubMed ID: 21041283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.